Make An Appointment Make A Payment Event Registration
Make an appointment

Lawrence Goldberg, M.D.

Lawrence Goldberg, M.D.

After completing his residency at the Albert Einstein College of Medicine, Bronx Municipal Hospital Center, followed by a fellowship in Gastroenterology at Montefiore Hospital and Medical Center, Dr. Goldberg has held the positions of Chief, Division of Gastroenterology, Assistant Professor of Medicine, Director of the Fellowship Program and Director of the Endoscopy Laboratory at University Hospital in Jacksonville, Florida. He is the past Chairman of the division of Gastroenterology at St. Luke’s/MAYO Hospital., Jacksonville. Dr. Goldberg remains active in the advancements in gastroenterology, serving as a principle investigator in several on going clinical research studies at the Borland Groover Clinic.



Office locations

Southside Office

Practicing since

1978

Certifications

  • National Board of Medical Examiners, 1974
  • American Board of Internal Medicine, 1976
  • Subspecialty Certification in Gastroenterology, 1979

National Provider Identifier

1699772483

Licensure

Florida, New York

Communicate with your physician’s staff through My BGC Health.

Professional Clinical Positions

Professional Clinical Positions
1995 - Present Borland-Groover Clinic, P.A. Jacksonville, Florida
1983 - 1995 Digestive Disease Associates Jacksonville, Florida
1995 - 1997 Executive, Medical Staff, St. Luke’s Hospital Jacksonville, Florida
1994 - 2005 Credentials Committee, St. Luke’s Hospital Jacksonville, Florida
1993 - 2002 Chief, Division of Gastroenterology, St. Luke’s Hospital Jacksonville, Florida
1990 - 2000 Credentials Committee, Baptist Medical Center Jacksonville, Florida
1990 - 1991 Vice Chairman, Department of Medicine, Baptist Medical Center Jacksonville, Florida
1980 - 1983 Member of Internal Medicine Advisory Committee, University Hospital of Jacksonville Jacksonville, Florida
1978 - 1983 Director of Gastroenterology, Endoscopy Laboratory, University Hospital of Jacksonville Jacksonville, Florida
1978 - 1983 Directory of Gastroenterology, Fellowship Program, University Hospital of Jacksonville Jacksonville, Florida
1978 - 1995 Assistant Professor of Medicine, University of Florida/JHEP Jacksonville, Florida
1978 - 1983 Chief, Division of Gastroenterology, University Hospital of Jacksonville Jacksonville, Florida

Medical Education

Medical Education
1969 - 1973 M.D., New York University School of Medicine New York, New York

Postgraduate Education

Postgraduate Education
1976 - 1978 Fellow in Gastroenterology Montefiore Hospital and Medical Center Bronx, New York
1973 - 1976 Internship in Internal Medicine Bronx Municipal Hospital Center, Albert Einstein College of Medicine Bronx, New York
1973 - 1976 Junior Assistant Resident in Internal Medicine Bronx Municipal Hospital Center, Albert Einstein College of Medicine Bronx, New York
1973 - 1976 Senior Assistant Resident in Internal Medicine Bronx Municipal Hospital Center, Albert Einstein College of Medicine Bronx, New York

Undergraduate Education

Undergraduate Education
1965 - 1969 B.A., Cum Laude, Psychology University of Pennsylvania Philadelphia, Pennsylvania

Professional Associations

  • Duval County Medical Society
  • Florida Medical Society
  • American College of Physicians
  • American Society of Gastrointestinal Endoscopy
  • American Gastrointestinal Association

Publications

Brand L.J., Goldberg L.S., Bernstein L., & Greenberg G., “The effect of Bacterially Produced Vitamin B-12 Analogues (Cobamides) on the In-Vitro Abbsorptionof Cyanocobalamin”. The American Journal of Clinical Nutrition 32:1832 September 1979.

Brand L.J., Boley S.J., Goldberg L.S., Mitsudo S.M., Berman A.J., “Colitis in the Elderly:  A Reappraisal”, The American Journal of Gastroenterology 76:239 September 1981.

Sands,B E, Kozarek, R. Spainhook J., Barish, C., Becker, S., Goldberg, L., Katz, S., Goldblum, R., Harrigon, R. MPH, Hilton, D. Ms., Hanaver, S., “Safety and Tolerability of Concurrent Natalzumab Treatment for Patients with Crohn’s Disease not in Remission while receiving Infliximab.” Inflammatory Bowel Disease 13:2, January 2007.

Targan, S.,  Feagan, B., Fedorak, R., Lashner, B., Panaccione, R., Volfoua, M., Wolf, D., Hernandez, C., Bornstein, G., Sandborn, W., * ENCORE Trial Group: “Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial.” Gastroenterology 132: 1672 May 2007.
* Lawrence Goldberg, MD. And Borland-Groover Clinic included in ENCORE Trial Group.

“Primary Care Update:  Home Study Course; Digestive Disease Disorders Section” for Georgia Academy of Family Practice Education Foundation 1981.

Abstracts

Review of Gastroenterology, MKSAP V Review Course Sponsored by Jacksonville Health Education Programs, 1980.

  • Ascend III - 2006444, Moderately active Ulcerative Colitis. Sub Investigator, 2007
  • Abbott UC - M06-827, Ulcerative Colitis. Primary Investigator, 2007
  • Shire UC - SPD476-404, Ulcerative Colitis. Primary Investigator, 2007
  • Shire - SPD476-313, Study evaluating the safety and efficacy of SPD476 vs. placebo over 104 weeks in prevention of recurrence of diverticulitis. Primary Investigator, 2007
  • Shire UC - SPD476-313, Study to assess clinical recurrence related to compliance w/ treatment w/ mmx mesaliamine 2.4g/day given once daily for the maintenance of quiescent Ulcerative Colitis. Primary Investigator, 2007
  • Celltech - BZUC 3003, Moderate to severe Crohns disease. Primary Investigator, 2007
  • Pharmos - VPI-TOFP-203, Study of 100, 200, and 300 mg BID Dextofisopam in Female Outpatients with Irritable Bowel Syndrome. Sub Investigator, 2007
  • Roche - NV18210, Study evaluating the efficacy and safety of 16 week vs. 24 week treatment w/ Pegasys in combination w/ copegus in Interferon-naive patients w/ Chronic Hepatitis C genotype 2/3 virus infection. Sub Investigator, 2007
  • Cospar 1 - C87059, A Phase IIIb multi-center, double-blind, placebo-controlled, randomized trial to examine the corticosteroid-sparing effect of certolizumab pegol in patients with moderate to severe Crohn’s disease. Sub Investigator, 2007
  • Cospar 2 - C87065 (COSPAR 2 rollover):  An open-label, multi-center trial to examine the long term safety, efficacy, and corticosteroid-sparing effect of certolizumab pegol in patients with moderate to severe Crohn’s disease who have failed tapering of corticosteroids, needed corticosteroids after completion of tapering, or have successfully completed the trial. Sub Investigator, 2007
  • Abbott - M04-690, Moderate to Severe Crohns Disease. Primary Investigator, 2007
  • Centecor - C0168T67, Crohns Disease ( Infusion). Sub Investigator, 2007
  • Centecor - C0379T07, Crohns Disease. Sub Investigator, 2007
  • ELN100226 - CD351, Crohns Disease for patients that have recently participated in Angeren studies. Primary Investigator, 2007
  • Abbott - M06-808, Moderate to Severe Crohns Disease. Primary Investigator, 2007
  • Abbott - M04-691, Moderate to Severe Crohns Disease. Primary Investigator, 2006
  • Novartis - CDNK333B2202, study to evaluate the efficacy and safety of DNK333 25mg B.i.d. given orally for 4 weeks in female patients with Diarrhea-predominant Irritable Bowel Syndrome (IBS-D). Sub Investigator, 2006
  • Sonic - C0168T67, Trial Comparing REMICADE (infliximab) and REMICADE plus Azathioprine to Azathioprine in the Treatment of Patients with Crohn’s Disease to both Immunomodulators and Biologic TherapyStudy of Biologic and Immunomodulator Patients in Crohn’s Disease. Sub Investigator, 2006
  • Inflabloc - SB-767905/014, Treatment of Opiod induced IBD in adults w/ opiod therapy for Persistent non-cancer pain. Sub Investigator, 2006
  • Abbott - M06-827, Moderate to Severe Ulcerative Colitis. Primary Investigator, 2006
  • MGI - 3000-0522, Study To Assess The Efficacy And Safety Of Aquavan (Fospropofol Disodium) Injection For Minimal-To Moderate Sedation In Patients Undergoing Colonoscopy. Sub Investigator, 2006
  • MGI - 3000-0523, 3000-0523:  Single arm study to assess the saftey of Aquavan injection for minimal to moderate sedation in patients undergoing minor surgical procedures, 2006
  • Otsuka - 197-02-218,  Study, of the Efficacy and Safety of OPC-6535 Tabletsin the Treatment of Subjects with Active Ulcerative Colitis. Sub Investigator, 2006
  • Salix - MPUC3003, Placebo- controlled trial to evaluate the use of mesalamine pellet formulation 1.56 QD to mild remission from mild to moderate Ulcerative Colitis. Sub Investigator, 2006
  • Salix - RFIB2001, Study to assess the efficacy and safety of three different doses (275, 550 and 1100) of Rifaximin administered bid for either two of four weeks I the treatment of patients w/ Diarrhea associated IBS. Sub Investigator, 2006
  • Salix - MPUC 3005, Treatment extension trial to evaluate the long-term safety and tolerability of mesalimine pellet formulation. Sub investigator, 2006
  • Roche - MV17150, Study examining the effects of duration of treatment and of a high induction dose of Pegasys in combination w. daily copegus in patients w/ Chronic Hepatitis C who did not respond to previous Peg interferon alfa-2b/ Ribavirin. Sub Investigator, 2006
  • Roche - NV17317, Study evaluating the efficacy and safety of 16-week vs. 24 week treatment w. Pegasys in combination w/ copegus in interferon-naïve patients w/ Chronic Hepatitis C Genotype 2 or 3 virus infection. Sub Investigator, 2005
  • Berlex - 308180, Saragramaostim (Leukine) retreatment for Active Crohns disease patients. Primary Investigator, 2005
  • SB-767905/014, Treatment of Opiod induced IBD in adults w/ opiod therapy for Persistent non-cancer pain. Sub Investigator, 2005
  • Luitpold - 1VIT05006, Cross-Over Study to Investigate the Safety of Intravenous VIT-45 in Patients with Iron Deficiency Anemia. Sub Investigator, 2005
  • Maintenance Ulcerative Colitis Otsuka - 197-02-220, Comparison Study of the Efficacy and Safety of 25mg QD and 50mg QD of OPC-6535 Oral Tablets and 800mg BID of Asacol® in the Maintenance of Remission in Subjects with Ulcerative Colitis. Sub Investigator, 2005
  • Elan - ELN100226 - CD351, Crohns Disease. Primary Investigator, 2005
  • CL003 - 282 , Moderate to severe Crohns Disease. Sub Investigator, 2005
  • Elan - ELN100226 - C0307, Patient with moderate to severe Crohns Disease w/ C reactive Protein. Primary Investigator, 2004
  • Novartis - CHTF91962203, study to assess the effect of tegaserod 2 mg t.i.d. and 6 mg t.i.d., on dyspeptic symptoms in diabetic patients with symptoms of diabetic gastropathy. Sub Investigator, 2004
  • Inkline - INKP-102-04-01, Colon Cleansing efficacy and safety of a new microcrystalline cellulose-free formulation of sodium phosphate tablets compared to visicol. Sub Investigator, 2004
  • Glaxo - S3B30048, Female Subjects with Severe Diarrhea-Predominant IBS Who’ve Failed Conventional Therapy. Sub Investigator, 2004
  • Astra Zeneca - D9612L00062, Gastro Esophageal Reflux Disease. Sub Investigator, 2003
  • AN100226 - CD303, Crohn’s Disease Remission. Primary Investigator, 2003
  • AN100226 - CD301, Moderate to Severe Crohn’s. Primary Investigator, 2003
  • Axcan - ITOFD04 - 01, Functional Dyspepsia. Sub Investigator, 2003
  • Dac - 1008, Moderate to Severe Ulcerative Colitis. Sub Investigator, 2003
  • Elan - ELN100226 - CD306, Crohns Disease - Remicade, Primary Investigator, 2003
  • S3B30048 - Female Subjects with Severe Diarrhea-Predominant Irritable Bowel Syndrome Who Have Failed Conventional Therapy. Sub Investigator, 2003
  • Isis - 2302-CS20, Antisense Inhibitor of ICAM-1, for the Treatment of Patients with Active Crohn’s Disease. Sub Investigator, 2002
  • RAB - USA - 18, GERD in patients w/ acute erosive Esophagitis. Sub Investigator, 2002